Although mGluR5 antagonists (e.g., MPEP, MTEP) have a strong preclinical case for treating epilepsy and depression comorbidity, their path to clinical viability for comorbidity is not entirely straightforward [226]. Here, GRM5 is linked to depressive symptom measurement.